Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2013 · 10-Q
Revenue$34.26M$34.26M+7.8% vs Q3 2012 Net Income-$2.14M-$2.14MN/M vs Q3 2012 EPS Diluted-$0.15-$0.15N/M vs Q3 2012 Gross Profit$4,696,000−20.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$811,000−78.0% Free Cash Flowderived$119,000−96.7% Margins · derivedGross margin13.7%−5.0 pt vs Q3 2012
Operating margin-6.0%−3.6 pt vs Q3 2012
Net margin-6.2%−3.0 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 13, 2013 · 44 d after period end